CTLA4 and neoplasm: Meanwhile, ICIs targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4), such as ipilimumab, and programmed death-1 (PD-1), such as nivolumab or pembrolizumab, alone or in combination can result in sustained tumor regression with the possibility of prolonged survival [2,3,4,5].